Apogee Therapeutics, Inc.
Clinical trials sponsored by Apogee Therapeutics, Inc., explained in plain language.
A biotech company developing antibody therapies for inflammatory and immunologic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New eczema drug combo enters early human testing
Disease control OngoingThis early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…
Phase: PHASE1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
New asthma drug enters early human testing
Symptom relief OngoingThis early-stage study tests a new drug called APG777 in 31 adults with mild-to-moderate asthma. The main goal is to check if the drug is safe and how the body handles it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug…
Phase: PHASE1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC